Cargando…
Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis
Antibody-based therapies that inhibit pro-inflammatory cytokine signalling are commonly used in dermatology. Paradoxically, these biological agents may induce or exacerbate paradoxical reactions. Recently, it has been reported that the treatment of eczema with dupilumab can lead to the development o...
Autores principales: | Li, Yanyan, Liu, Hong, Zhang, Furen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238968/ https://www.ncbi.nlm.nih.gov/pubmed/37275804 http://dx.doi.org/10.4103/ijd.ijd_871_22 |
Ejemplares similares
-
Psoriasis and Atopic Dermatitis
por: Griffiths, Christopher E. M., et al.
Publicado: (2017) -
Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis
por: Varma, Aakaash, et al.
Publicado: (2020) -
Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
por: Cline, Abigail, et al.
Publicado: (2019) -
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019) -
S100 Proteins in the Pathogenesis of Psoriasis and Atopic Dermatitis
por: Saito-Sasaki, Natsuko, et al.
Publicado: (2023)